Reclassification Recommendations for Psilocybin From Schedule I to Schedule IV
Razi Berry If phase III clinical trials are successful, researchers suggest categorizing the drug as schedule IV In an evaluation of the safety and abuse research on the drug in hallucinogenic mushrooms, Johns Hopkins researchers suggest that if it clears phase III clinical trials, psilocybin should be re-categorized from a schedule I drug—one with no […]